Bile acid indices as biomarkers for liver diseases I: Diagnostic markers.
Bile acid indices
Bile acids
Biomarker
Diagnosis
Hepatobiliary diseases
Liver diseases
Journal
World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
05
01
2021
revised:
11
02
2021
accepted:
22
03
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
ppublish
Résumé
Hepatobiliary diseases result in the accumulation of toxic bile acids (BA) in the liver, blood, and other tissues which may contribute to an unfavorable prognosis. To discover and validate diagnostic biomarkers of cholestatic liver diseases based on the urinary BA profile. We analyzed urine samples by liquid chromatography-tandem mass spectrometry and compared the urinary BA profile between 300 patients with hepatobiliary diseases Total and individual BA concentrations were higher in all patients. The percentage of secondary BA (lithocholic acid and deoxycholic acid) was significantly lower, while the percentage of primary BA (chenodeoxycholic acid, cholic acid, and hyocholic acid) was markedly higher in patients compared to controls. In addition, the percentage of taurine-amidation was higher in patients than controls. The increase in the non-12α-OH BA was more profound than 12α-OH BA (cholic acid and deoxycholic acid) causing a decrease in the 12α-OH/ non-12α-OH ratio in patients. This trend was stronger in patients with more advanced liver diseases as reflected by the model for end-stage liver disease score and the presence of hepatic decompensation. The percentage of sulfation was also higher in patients with more severe forms of liver diseases. BA indices have much lower inter- and intra-individual variability compared to absolute BA concentrations and changes of BA indices are associated with the risk of developing liver diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatobiliary diseases result in the accumulation of toxic bile acids (BA) in the liver, blood, and other tissues which may contribute to an unfavorable prognosis.
AIM
OBJECTIVE
To discover and validate diagnostic biomarkers of cholestatic liver diseases based on the urinary BA profile.
METHODS
METHODS
We analyzed urine samples by liquid chromatography-tandem mass spectrometry and compared the urinary BA profile between 300 patients with hepatobiliary diseases
RESULTS
RESULTS
Total and individual BA concentrations were higher in all patients. The percentage of secondary BA (lithocholic acid and deoxycholic acid) was significantly lower, while the percentage of primary BA (chenodeoxycholic acid, cholic acid, and hyocholic acid) was markedly higher in patients compared to controls. In addition, the percentage of taurine-amidation was higher in patients than controls. The increase in the non-12α-OH BA was more profound than 12α-OH BA (cholic acid and deoxycholic acid) causing a decrease in the 12α-OH/ non-12α-OH ratio in patients. This trend was stronger in patients with more advanced liver diseases as reflected by the model for end-stage liver disease score and the presence of hepatic decompensation. The percentage of sulfation was also higher in patients with more severe forms of liver diseases.
CONCLUSION
CONCLUSIONS
BA indices have much lower inter- and intra-individual variability compared to absolute BA concentrations and changes of BA indices are associated with the risk of developing liver diseases.
Identifiants
pubmed: 33959226
doi: 10.4254/wjh.v13.i4.433
pmc: PMC8080550
doi:
Types de publication
Journal Article
Langues
eng
Pagination
433-455Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that there is no conflict of interests in this study.
Références
Hepatology. 2002 Jun;35(6):1409-19
pubmed: 12029626
J Biol Chem. 1998 Apr 17;273(16):10046-50
pubmed: 9545351
Gastroenterology. 1999 Dec;117(6):1370-9
pubmed: 10579978
Clin Sci Mol Med. 1977 Jan;52(1):51-65
pubmed: 606464
Cell Mol Life Sci. 2008 Aug;65(16):2461-83
pubmed: 18488143
Am J Gastroenterol. 2010 Mar;105(3):596-8
pubmed: 20203641
Biochim Biophys Acta. 2005 Dec 30;1738(1-3):54-62
pubmed: 16332456
Pediatr Int. 2003 Jun;45(3):281-3
pubmed: 12828581
Hepatology. 1991 Nov;14(5):920-6
pubmed: 1937396
Drug Metab Dispos. 2015 Jul;43(7):1061-70
pubmed: 25948711
J Perinat Med. 2007;35(6):486-91
pubmed: 18052835
Gastroenterol Jpn. 1984 Apr;19(2):104-9
pubmed: 6735068
Liver Int. 2012 Oct;32(9):1407-14
pubmed: 22679906
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:53-62
pubmed: 24212143
Genes Dis. 2018 Jan 31;5(4):358-366
pubmed: 30591938
Annu Rev Physiol. 2002;64:635-61
pubmed: 11826283
Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G88-94
pubmed: 15746212
J Toxicol Sci. 2009 Feb;34(1):27-38
pubmed: 19182433
J Clin Exp Hepatol. 2016 Jun;6(2):87-93
pubmed: 27493455
PLoS One. 2011;6(7):e22094
pubmed: 21760958
Gut. 2010 Jul;59(7):963-8
pubmed: 20581243
Gastroenterology. 1999 Feb;116(2):401-10
pubmed: 9922322
Gastroenterology. 2001 Jun;120(7):1801-9
pubmed: 11375960
Dig Liver Dis. 2010 Jun;42(6):409-18
pubmed: 20434968
Clin Transl Sci. 2011 Jun;4(3):210-8
pubmed: 21707953
Biochem J. 1991 Dec 1;280 ( Pt 2):373-7
pubmed: 1747109
Gastroenterology. 1975 Mar;68(3):545-53
pubmed: 1112456
Drug Metab Dispos. 2006 Sep;34(9):1575-81
pubmed: 16760228
Food Chem Toxicol. 2007 Sep;45(9):1551-7
pubmed: 17658209
Toxicol Sci. 2000 Sep;57(1):177-85
pubmed: 10966524
Am J Surg. 2004 Nov;188(5):580-3
pubmed: 15546574
Dig Liver Dis. 2012 Apr;44(4):303-10
pubmed: 22169272
Gastroenterology. 2002 Nov;123(5):1659-66
pubmed: 12404240
Arch Intern Med. 1972 Oct;130(4):606-17
pubmed: 4627840
J Pharm Biomed Anal. 2011 Jul 15;55(5):1111-9
pubmed: 21530128
J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S103-10
pubmed: 15758645
Hepatology. 2006 Sep;44(3):746-64
pubmed: 16941705
Hepatology. 1985 May-Jun;5(3):492-5
pubmed: 3997078
J Appl Toxicol. 2018 Oct;38(10):1336-1352
pubmed: 29845631
World J Gastroenterol. 2017 Feb 7;23(5):763-775
pubmed: 28223721
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Nat Rev Drug Discov. 2008 Aug;7(8):678-93
pubmed: 18670431
Drug Metab Rev. 2010 Aug;42(3):437-45
pubmed: 20028269
J Hepatol. 2003 Nov;39(5):693-702
pubmed: 14568249
Gut. 1976 Nov;17(11):861-9
pubmed: 1001976
J Biol Chem. 2001 Nov 9;276(45):41690-9
pubmed: 11535594
Arch Intern Med. 1999 Dec 13-27;159(22):2647-58
pubmed: 10597755
J Hepatol. 2009 Jan;50(1):69-79
pubmed: 19012987
Toxicology. 2008 Mar 20;245(3):194-205
pubmed: 18291570
Gastroenterology. 2000 Feb;118(2):422-30
pubmed: 10648470
PLoS One. 2013 Nov 14;8(11):e80994
pubmed: 24244729
Hepatology. 2015 Oct;62(4):1315-7
pubmed: 26122550
J Biol Chem. 2000 Jan 28;275(4):2905-10
pubmed: 10644759
Toxicol Sci. 2009 Apr;108(2):225-46
pubmed: 19131563
J Biol Chem. 2000 Jun 30;275(26):20210-6
pubmed: 10770953
Biochem J. 2003 Apr 15;371(Pt 2):361-7
pubmed: 12523936
Adv Pharmacol. 2015;74:263-302
pubmed: 26233910
J Hepatol. 1997 Aug;27(2):346-57
pubmed: 9288610
Toxicol Sci. 2015 Feb;143(2):308-18
pubmed: 25344563
J Hepatol. 2004 Dec;41(6):1017-25
pubmed: 15582136
PLoS One. 2018 Mar 7;13(3):e0193824
pubmed: 29513725
World J Gastroenterol. 2009 Feb 21;15(7):804-16
pubmed: 19230041
Toxicol Sci. 2015 Feb;143(2):296-307
pubmed: 25344562
Hepatology. 2005 Jun;41(6):1407-32
pubmed: 15880505
Gastroenterology. 2012 Feb;142(2):355-65.e1-4
pubmed: 22057115